{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:31:26Z","timestamp":1789011086375,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Real-world data and study data regarding therapy with Emicizumab in pediatric cohorts with haemophilia A is scarce. Especially, data on previously untreated pediatric patients (PUPs) and minimally treated patients (MTPs) are missing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirteen pediatric patients with haemophilia A and treatment with Emicizumab were retrospectively evaluated for Annual Bleeding Rates (ABR) pre-and post-Emicizumab treatment. Safety data and data on management of minor surgery as well as laboratory results were collected. Additionally, we describe the clinical features of two PUPs and one MTP that are included in our cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median age at initiation of Emicizumab was 5.3 (range: 0.26\u201317.5) years, three patients were younger than one year at initiation of treatment with Emicizumab. Median follow-up time on Emicizumab was 23.8 (range:\u00a00.7\u201340) months. Total ABR (<jats:italic>p<\/jats:italic>\u2009=\u20090.009) as well as spontaneous (<jats:italic>p<\/jats:italic>\u2009=\u20090.018), traumatic (<jats:italic>p\u2009<\/jats:italic>=\u20090.018), and joint (<jats:italic>p<\/jats:italic>\u2009=\u20090.027) ABR reduced significantly post-Emicizumab transition. Safety profile was favourable as only one local site reaction occurred; no cessation of treatment was necessary. Surgery was successfully performed in three patients receiving rFVlla pre- and post-surgery. Emicizumab trough levels showed a median of 43.2\u00a0\u03bcg\/ml (range:\u00a023.9\u201356.8) after three doses of 3\u00a0mg\/kg and 51.9\u00a0\u03bcg\/ml (range:\u00a030.4\u201375) at first follow-up with 1.5\u00a0mg\/kg.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Emicizumab is safe and efficient in pediatric patients with and without inhibitors. More data on larger multicenter cohorts and especially on PUPs\/MTPs are still needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-022-03546-1","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T02:02:36Z","timestamp":1660528956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab"],"prefix":"10.1186","volume":"22","author":[{"given":"Hannah","family":"Glonnegger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Malvestiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00fcchsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Zieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"issue":"9","key":"3546_CR1","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1111\/jth.15444","volume":"19","author":"R Gualtierotti","year":"2021","unstructured":"Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost JTH. 2021;19(9):2112\u201321. https:\/\/doi.org\/10.1111\/jth.15444.","journal-title":"J Thromb Haemost JTH"},{"key":"3546_CR2","doi-asserted-by":"publisher","unstructured":"H.-H. Brackmann, G. C. 2nd White, E. Berntorp, T. Andersen, und C. Escuriola-Ettingshausen. Immune tolerance induction: What have we learned over time? Haemoph. Off J World Fed Hemoph, Bd. 24 Suppl 3, S. 3\u201314,\u00a02018.\u00a0https:\/\/doi.org\/10.1111\/hae.13445.","DOI":"10.1111\/hae.13445"},{"key":"3546_CR3","doi-asserted-by":"publisher","unstructured":"J. Mahlangu u.\u00a0a. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med, Bd. 379, Nr. 9, S. 811\u2013822,\u00a02018.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1803550.","DOI":"10.1056\/NEJMoa1803550"},{"key":"3546_CR4","doi-asserted-by":"publisher","unstructured":"M. Shima u.\u00a0a. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med, Bd. 374, Nr. 21, S. 2044\u20132053,\u00a0\u00a02016.\u00a0\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1511769.","DOI":"10.1056\/NEJMoa1511769"},{"key":"3546_CR5","doi-asserted-by":"publisher","unstructured":"J. Oldenburg u.\u00a0a. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med, Bd. 377, Nr. 9, S. 809\u2013818,\u00a0\u00a02017.\u00a0\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1703068.","DOI":"10.1056\/NEJMoa1703068"},{"key":"3546_CR6","doi-asserted-by":"publisher","unstructured":"G. Young u.\u00a0a. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood, Bd. 134, Nr. 24, S. 2127\u20132138,\u00a0\u00a02019,\u00a0https:\/\/doi.org\/10.1182\/blood.2019001869.","DOI":"10.1182\/blood.2019001869"},{"key":"3546_CR7","doi-asserted-by":"publisher","unstructured":"S. W. Pipe u.\u00a0a. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol, Bd. 6, Nr. 6, S. e295\u2013e305,\u00a0\u00a02019.\u00a0\u00a0https:\/\/doi.org\/10.1016\/S2352-3026(19)30054-7.","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"3546_CR8","doi-asserted-by":"publisher","unstructured":"A. A. Barg u.\u00a0a. Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Br J Haematol, Bd. 191, Nr. 2, S. 282\u2013290,\u00a02020.\u00a0\u00a0https:\/\/doi.org\/10.1111\/bjh.16964.","DOI":"10.1111\/bjh.16964"},{"key":"3546_CR9","doi-asserted-by":"publisher","unstructured":"A. A. Barg u.\u00a0a. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Pediatr Blood Cancer, Bd. 66, Nr. 11, S. e27886,\u00a02019.\u00a0\u00a0https:\/\/doi.org\/10.1002\/pbc.27886.","DOI":"10.1002\/pbc.27886"},{"key":"3546_CR10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2147\/DDDT.S167731","volume":"14","author":"S Le Quellec","year":"2020","unstructured":"Le Quellec S. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A. Drug Des Devel Ther. 2020;14:469\u201381. https:\/\/doi.org\/10.2147\/DDDT.S167731.","journal-title":"Drug Des Devel Ther"},{"key":"3546_CR11","doi-asserted-by":"publisher","unstructured":"I. McCary u.\u00a0a. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemoph Off J World Fed Hemoph, Bd. 26, Nr. 4, S. 631\u2013636, 2020,\u00a0\u00a0https:\/\/doi.org\/10.1111\/hae.14005.","DOI":"10.1111\/hae.14005"},{"key":"3546_CR12","doi-asserted-by":"publisher","unstructured":"J. Garcia und A. Zia. Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab. Pediatr.Blood Cancer, Bd. 68, Nr. 5, S. e28942, Mai 2021.\u00a0\u00a0https:\/\/doi.org\/10.1002\/pbc.28942.","DOI":"10.1002\/pbc.28942"},{"key":"3546_CR13","doi-asserted-by":"publisher","unstructured":"M. Shima u.\u00a0a. A multicentre, open-label study of emicizumab given every 2 or 4\u00a0weeks in children with severe haemophilia A without inhibitors. Haemoph Off J World Fed. Hemoph, Bd. 25, Nr. 6, S. 979\u2013987, Nov. 2019.\u00a0\u00a0https:\/\/doi.org\/10.1111\/hae.13848.","DOI":"10.1111\/hae.13848"},{"issue":"6","key":"3546_CR14","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1111\/hae.14432","volume":"27","author":"E Hassan","year":"2021","unstructured":"Hassan E, Jonathan L, Jayashree M. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors. Haemoph Off J World Fed Hemoph. 2021;27(6):e698\u2013703. https:\/\/doi.org\/10.1111\/hae.14432.","journal-title":"Haemoph Off J World Fed Hemoph"},{"key":"3546_CR15","doi-asserted-by":"publisher","unstructured":"K. Holstein u.\u00a0a. Practical Guidance of the GTH Haemophilia Board on the Use of Emicizumab in Patients with Haemophilia A. Hamostaseologie, Bd. 40, Nr. 5, S. 561\u2013571, 2020.\u00a0\u00a0https:\/\/doi.org\/10.1055\/a-1127-6476.","DOI":"10.1055\/a-1127-6476"},{"key":"3546_CR16","doi-asserted-by":"publisher","unstructured":"F. Jonsson, C. Schmitt, C. Petry, F. Mercier, N. Frey, und S. Retout. Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with\/Without Inhibitors Against Factor VIII. Clin. Pharmacokinet. Bd. 60, Nr. 7, S. 931\u2013941, 2021.\u00a0\u00a0https:\/\/doi.org\/10.1007\/s40262-021-01006-0.","DOI":"10.1007\/s40262-021-01006-0"},{"issue":"9","key":"3546_CR17","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1055\/s-0039-1692427","volume":"119","author":"J M\u00fcller","year":"2019","unstructured":"M\u00fcller J, Pekrul I, P\u00f6tzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A. Thromb Haemost. 2019;119(9):1384\u201393. https:\/\/doi.org\/10.1055\/s-0039-1692427.","journal-title":"Thromb Haemost"},{"issue":"1","key":"3546_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1055\/s-0039-3402805","volume":"40","author":"K Kurnik","year":"2020","unstructured":"Kurnik K, Bidlingmaier C, Olivieri M. How Do I Counsel Parents of a Newly Diagnosed Boy with Haemophilia A? Hamostaseologie. 2020;40(1):88\u201396. https:\/\/doi.org\/10.1055\/s-0039-3402805.","journal-title":"Hamostaseologie"},{"key":"3546_CR19","unstructured":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors. Accessed: 17.\u00a02022.\u00a0\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04431726"},{"key":"3546_CR20","doi-asserted-by":"publisher","unstructured":"G. Young. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Adv., Bd. 2, Nr. 20, S. 2780\u20132782, 2018.\u00a0\u00a0https:\/\/doi.org\/10.1182\/bloodadvances.2018015842.","DOI":"10.1182\/bloodadvances.2018015842"},{"key":"3546_CR21","doi-asserted-by":"publisher","unstructured":"S. Le Quellec und C. Negrier. Emicizumab should be prescribed independent of immune tolerance induction. Blood Adv, Bd. 2, Nr. 20, S. 2783\u20132786,\u00a0\u00a02018.\u00a0\u00a0https:\/\/doi.org\/10.1182\/bloodadvances.2018015859.","DOI":"10.1182\/bloodadvances.2018015859"},{"issue":"2","key":"3546_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/17474086.2021.1875817","volume":"14","author":"M Carcao","year":"2021","unstructured":"Carcao M, Mancuso ME, Young G, Jim\u00e9nez-Yuste V. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Rev Hematol. 2021;14(2):143\u20138. https:\/\/doi.org\/10.1080\/17474086.2021.1875817.","journal-title":"Expert Rev Hematol"},{"key":"3546_CR23","doi-asserted-by":"publisher","unstructured":"C. Escuriola-Ettingshausen u.\u00a0a. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: Recommendations from a German expert panel. Haemoph Off J World Fed Hemoph, Bd. 27, Nr. 3, S. e305\u2013e313, 2021.\u00a0\u00a0https:\/\/doi.org\/10.1111\/hae.14010.","DOI":"10.1111\/hae.14010"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03546-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-022-03546-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-022-03546-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T02:02:58Z","timestamp":1660528978000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-022-03546-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3546"],"URL":"https:\/\/doi.org\/10.1186\/s12887-022-03546-1","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval by the Ethics Committee of the University of Freiburg was obtained prior to inclusion of patients into the retrospective analysis.\u00a0All methods were carried out in accordance with relevant guidelines and regulations. Parents gave written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the parents for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have no competing interests to declare pertaining to this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"487"}}